@article{article, title  = {{Immunogenicity and safety of AZD2816, a beta (B.1.351) variant COVID-19 vaccine, and AZD1222 (ChAdOx1 nCoV-19) as third-dose boosters for previously vaccinated adults: a multicentre, randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study in the UK and Poland}},

 publisher = {{Elsevier BV}},

 url = {{http://dx.doi.org/10.1016/s2666-5247(23)00177-5 }},

 year = {{2023}},

 month = {{9}},

 author = {{Ramasamy MN and Kelly EJ and Seegobin S and Dargan PI and Payne R and Libri V and Adam M and Aley PK and Martinez-Alier N and Church A and Jepson B et al}},

 doi = {{10.1016/s2666-5247(23)00177-5}},

 volume = {{4}},

 journal = {{The Lancet Microbe}},

 issue = {{11}},

 pages = {{e863-e874}},

 note = {{Accessed on 2024/09/19}}}